# Phase-one mesothelioma study reports PRX3 inhibitor results

_Published Thursday, September 17, 2026 at 6:07 AM EDT · Science · Latest · Tier 2 — Notable_

![Phase-one mesothelioma study reports PRX3 inhibitor results — Primary](https://www.sciencedaily.com/images/1920/lung-cancer-tumor-anatomy.webp)

Researchers at the University of Vermont and collaborators reported phase-one results for RSO-021, a clinical formulation of thiostrepton, in relapsed mesothelioma.

In 15 patients, the trial controlled disease progression in 67%; average progression-free survival was 4.2 months, roughly comparable with existing treatments. The treatment blocks PRX3, causing hydrogen peroxide to build up in tumor-cell mitochondria. The phase-one trial was conducted in the UK between 2022 and 2023, and phase two has since been completed; results are expected to be presented this year.

## Sources

- [All Top News -- ScienceDaily](https://www.sciencedaily.com/releases/2026/09/260915232136.htm)

---
Canonical: https://techandbusiness.org/newswire/SjH5QB9DQHDj06haGnaQRG
Published: 2026-09-17T10:07:21.225Z
Story chronology: 2026-09-17T05:11:51.000Z
Retrieved: 2026-09-17T12:14:30.106Z
Publisher: Tech & Business (techandbusiness.org)